Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia

Qunsheng Dai, Jianhua Huang, Brace Klitzman, Chunming Dong, Pascal J. Goldschmidt-Clermont, Keith L. March, Joseph Rokovich, Brian Johnstone, Edward J. Rebar, S. Kaye Spratt, Casey C. Case, Christopher D. Kontos, Brian H. Annex

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Background - Therapeutic angiogenesis seeks to promote blood vessel growth to improve tissue perfusion. Vascular endothelial growth factor (VEGF) exists in multiple isoforms. We investigated an engineered zinc finger-containing transcription factor plasmid designed to activate the endogenous VEGF gene (ZFP-VEGF). Methods and Results - New Zealand White rabbits (n=56) underwent unilateral femoral artery ligation and excision. At day 10 postoperatively, the ischemic muscle received ZFP treatment (500 μg ZFP-VEGF plasmid) or no ZFP treatment (β-galactosidase, empty, or no plasmid). Group 1 (n=13) was harvested 3 days after injection to examine VEGF mRNA by real-time polymerase chain reaction and protein by ELISA. Groups 2 (n=13) and 3 (n=10) were harvested 11 days after injection. Group 2 was studied by histology and group 3, by histology and changes in blood flow. Groups 4 and 5 (n=10 each) were harvested 22 and 32 days after injection, respectively, and studied for changes in blood flow. In group 1, VEGF mRNA copy numbers were significantly higher for VEGF 121, VEGF165, VEGF189, and protein in the ZFP-VEGF-treatment versus no-ZFP-treatment arms. In groups 2 and 3, capillary density and proliferating cells were significantly greater and apoptosis significantly lower in the treatment versus no-treatment arms. Changes in the blood flow ratio of the ischemic to the nonischemic limb were significantly greater in the treatment versus no-ZFP-treatment groups (6.57±1.52% versus 3.38±0.87%, P<0.005; 13.15±1.77% versus 6.13±1.55%, P<0.001; and 20.16±2.84% versus 13.88±3.14%, P<0.01, for groups 3, 4, and 5, respectively). Conclusions - This engineered ZFP-VEGF-activating transcription factor may provide a novel approach to treat peripheral arterial disease.

Original languageEnglish
Pages (from-to)2467-2475
Number of pages9
JournalCirculation
Volume110
Issue number16
DOIs
StatePublished - Oct 19 2004

Fingerprint

Zinc Fingers
Hindlimb
Vascular Endothelial Growth Factor A
Plasmids
Transcription Factors
Ischemia
Rabbits
DNA
Therapeutics
Injections
Histology
Arm
Activating Transcription Factors
Galactosidases
Messenger RNA
Peripheral Arterial Disease
Femoral Artery
Ligation
Blood Vessels
Real-Time Polymerase Chain Reaction

Keywords

  • Angiogenesis
  • Apoptosis
  • Endothelium-derived factors
  • Growth substances
  • Muscle

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. / Dai, Qunsheng; Huang, Jianhua; Klitzman, Brace; Dong, Chunming; Goldschmidt-Clermont, Pascal J.; March, Keith L.; Rokovich, Joseph; Johnstone, Brian; Rebar, Edward J.; Spratt, S. Kaye; Case, Casey C.; Kontos, Christopher D.; Annex, Brian H.

In: Circulation, Vol. 110, No. 16, 19.10.2004, p. 2467-2475.

Research output: Contribution to journalArticle

Dai, Q, Huang, J, Klitzman, B, Dong, C, Goldschmidt-Clermont, PJ, March, KL, Rokovich, J, Johnstone, B, Rebar, EJ, Spratt, SK, Case, CC, Kontos, CD & Annex, BH 2004, 'Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia', Circulation, vol. 110, no. 16, pp. 2467-2475. https://doi.org/10.1161/01.CIR.0000145139.53840.49
Dai, Qunsheng ; Huang, Jianhua ; Klitzman, Brace ; Dong, Chunming ; Goldschmidt-Clermont, Pascal J. ; March, Keith L. ; Rokovich, Joseph ; Johnstone, Brian ; Rebar, Edward J. ; Spratt, S. Kaye ; Case, Casey C. ; Kontos, Christopher D. ; Annex, Brian H. / Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. In: Circulation. 2004 ; Vol. 110, No. 16. pp. 2467-2475.
@article{cba3961ea9074a75a73dcd942e03751c,
title = "Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia",
abstract = "Background - Therapeutic angiogenesis seeks to promote blood vessel growth to improve tissue perfusion. Vascular endothelial growth factor (VEGF) exists in multiple isoforms. We investigated an engineered zinc finger-containing transcription factor plasmid designed to activate the endogenous VEGF gene (ZFP-VEGF). Methods and Results - New Zealand White rabbits (n=56) underwent unilateral femoral artery ligation and excision. At day 10 postoperatively, the ischemic muscle received ZFP treatment (500 μg ZFP-VEGF plasmid) or no ZFP treatment (β-galactosidase, empty, or no plasmid). Group 1 (n=13) was harvested 3 days after injection to examine VEGF mRNA by real-time polymerase chain reaction and protein by ELISA. Groups 2 (n=13) and 3 (n=10) were harvested 11 days after injection. Group 2 was studied by histology and group 3, by histology and changes in blood flow. Groups 4 and 5 (n=10 each) were harvested 22 and 32 days after injection, respectively, and studied for changes in blood flow. In group 1, VEGF mRNA copy numbers were significantly higher for VEGF 121, VEGF165, VEGF189, and protein in the ZFP-VEGF-treatment versus no-ZFP-treatment arms. In groups 2 and 3, capillary density and proliferating cells were significantly greater and apoptosis significantly lower in the treatment versus no-treatment arms. Changes in the blood flow ratio of the ischemic to the nonischemic limb were significantly greater in the treatment versus no-ZFP-treatment groups (6.57±1.52{\%} versus 3.38±0.87{\%}, P<0.005; 13.15±1.77{\%} versus 6.13±1.55{\%}, P<0.001; and 20.16±2.84{\%} versus 13.88±3.14{\%}, P<0.01, for groups 3, 4, and 5, respectively). Conclusions - This engineered ZFP-VEGF-activating transcription factor may provide a novel approach to treat peripheral arterial disease.",
keywords = "Angiogenesis, Apoptosis, Endothelium-derived factors, Growth substances, Muscle",
author = "Qunsheng Dai and Jianhua Huang and Brace Klitzman and Chunming Dong and Goldschmidt-Clermont, {Pascal J.} and March, {Keith L.} and Joseph Rokovich and Brian Johnstone and Rebar, {Edward J.} and Spratt, {S. Kaye} and Case, {Casey C.} and Kontos, {Christopher D.} and Annex, {Brian H.}",
year = "2004",
month = "10",
day = "19",
doi = "10.1161/01.CIR.0000145139.53840.49",
language = "English",
volume = "110",
pages = "2467--2475",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "16",

}

TY - JOUR

T1 - Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia

AU - Dai, Qunsheng

AU - Huang, Jianhua

AU - Klitzman, Brace

AU - Dong, Chunming

AU - Goldschmidt-Clermont, Pascal J.

AU - March, Keith L.

AU - Rokovich, Joseph

AU - Johnstone, Brian

AU - Rebar, Edward J.

AU - Spratt, S. Kaye

AU - Case, Casey C.

AU - Kontos, Christopher D.

AU - Annex, Brian H.

PY - 2004/10/19

Y1 - 2004/10/19

N2 - Background - Therapeutic angiogenesis seeks to promote blood vessel growth to improve tissue perfusion. Vascular endothelial growth factor (VEGF) exists in multiple isoforms. We investigated an engineered zinc finger-containing transcription factor plasmid designed to activate the endogenous VEGF gene (ZFP-VEGF). Methods and Results - New Zealand White rabbits (n=56) underwent unilateral femoral artery ligation and excision. At day 10 postoperatively, the ischemic muscle received ZFP treatment (500 μg ZFP-VEGF plasmid) or no ZFP treatment (β-galactosidase, empty, or no plasmid). Group 1 (n=13) was harvested 3 days after injection to examine VEGF mRNA by real-time polymerase chain reaction and protein by ELISA. Groups 2 (n=13) and 3 (n=10) were harvested 11 days after injection. Group 2 was studied by histology and group 3, by histology and changes in blood flow. Groups 4 and 5 (n=10 each) were harvested 22 and 32 days after injection, respectively, and studied for changes in blood flow. In group 1, VEGF mRNA copy numbers were significantly higher for VEGF 121, VEGF165, VEGF189, and protein in the ZFP-VEGF-treatment versus no-ZFP-treatment arms. In groups 2 and 3, capillary density and proliferating cells were significantly greater and apoptosis significantly lower in the treatment versus no-treatment arms. Changes in the blood flow ratio of the ischemic to the nonischemic limb were significantly greater in the treatment versus no-ZFP-treatment groups (6.57±1.52% versus 3.38±0.87%, P<0.005; 13.15±1.77% versus 6.13±1.55%, P<0.001; and 20.16±2.84% versus 13.88±3.14%, P<0.01, for groups 3, 4, and 5, respectively). Conclusions - This engineered ZFP-VEGF-activating transcription factor may provide a novel approach to treat peripheral arterial disease.

AB - Background - Therapeutic angiogenesis seeks to promote blood vessel growth to improve tissue perfusion. Vascular endothelial growth factor (VEGF) exists in multiple isoforms. We investigated an engineered zinc finger-containing transcription factor plasmid designed to activate the endogenous VEGF gene (ZFP-VEGF). Methods and Results - New Zealand White rabbits (n=56) underwent unilateral femoral artery ligation and excision. At day 10 postoperatively, the ischemic muscle received ZFP treatment (500 μg ZFP-VEGF plasmid) or no ZFP treatment (β-galactosidase, empty, or no plasmid). Group 1 (n=13) was harvested 3 days after injection to examine VEGF mRNA by real-time polymerase chain reaction and protein by ELISA. Groups 2 (n=13) and 3 (n=10) were harvested 11 days after injection. Group 2 was studied by histology and group 3, by histology and changes in blood flow. Groups 4 and 5 (n=10 each) were harvested 22 and 32 days after injection, respectively, and studied for changes in blood flow. In group 1, VEGF mRNA copy numbers were significantly higher for VEGF 121, VEGF165, VEGF189, and protein in the ZFP-VEGF-treatment versus no-ZFP-treatment arms. In groups 2 and 3, capillary density and proliferating cells were significantly greater and apoptosis significantly lower in the treatment versus no-treatment arms. Changes in the blood flow ratio of the ischemic to the nonischemic limb were significantly greater in the treatment versus no-ZFP-treatment groups (6.57±1.52% versus 3.38±0.87%, P<0.005; 13.15±1.77% versus 6.13±1.55%, P<0.001; and 20.16±2.84% versus 13.88±3.14%, P<0.01, for groups 3, 4, and 5, respectively). Conclusions - This engineered ZFP-VEGF-activating transcription factor may provide a novel approach to treat peripheral arterial disease.

KW - Angiogenesis

KW - Apoptosis

KW - Endothelium-derived factors

KW - Growth substances

KW - Muscle

UR - http://www.scopus.com/inward/record.url?scp=6444236227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6444236227&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000145139.53840.49

DO - 10.1161/01.CIR.0000145139.53840.49

M3 - Article

VL - 110

SP - 2467

EP - 2475

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 16

ER -